16 assets in Cholangitis

Therapeutic assets addressing Cholangitis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ceftriaxone Cholangitis	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	P4	BB (67)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Cholangitis	Ankara City Hospital Bilkent	P2	B (57)
Meperidine Cholangitis	National University of Malaysia	P2	B (57)
Midazolam Cholangitis	National University of Malaysia	P2	B (57)
Gentamicin Cholangitis	National University of Malaysia	P2	CCC (53)
Propofol Cholangitis	Ankara City Hospital Bilkent	P2	CCC (53)
Ursodeoxycholic Acid Cholangitis	Children's Hospital of Fudan University	P2	CCC (53)
Cefaclor Anhydrous Cholangitis	Children's Hospital of Fudan University	N/A	D (30)
Cefuroxime Cholangitis	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	N/A	D (30)
Ciprofloxacin Cholangitis	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	N/A	D (30)
Glycyrrhizic Acid Cholangitis	Children's Hospital of Fudan University	N/A	D (30)
Imipenem Cholangitis	Children's Hospital of Fudan University	N/A	D (30)
Meropenem Cholangitis	Children's Hospital of Fudan University	N/A	D (30)
Ramifentanyl Cholangitis	Ankara City Hospital Bilkent	N/A	D (30)
Sulperazon Cholangitis	Children's Hospital of Fudan University	N/A	D (30)
Trimethoprim Cholangitis	Children's Hospital of Fudan University	N/A	D (30)